Combination PD-1/PD-L1 ICI + VEGFR-TKI — Competitive Intelligence Brief

Combination PD-1/PD-L1 ICI + VEGFR-TKI (Combination PD-1/PD-L1 ICI + VEGFR-TKI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor) Oncology Small molecule

Target snapshot

Combination PD-1/PD-L1 ICI + VEGFR-TKI (Combination PD-1/PD-L1 ICI + VEGFR-TKI) — University Hospital, Bordeaux. This combination blocks PD-1/PD-L1 immune checkpoints to enhance T-cell anti-tumor activity while simultaneously inhibiting VEGFR tyrosine kinases to suppress tumor angiogenesis and promote anti-angiogenic immune effects.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combination PD-1/PD-L1 ICI + VEGFR-TKI TARGET	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination class)

1. University Hospital, Bordeaux · 1 drug in this class